Assessment of Pathological Response to Neoadjuvant Therapy: Comparison Between Pertuzumab-Based and Non-Pertuzumab Protocols in HER2-Positive Breast Cancer

Akrami, M., Meshksar, A., Ghoddusi, J. M., Safarpour, M. M., Tahmasebi, S., Zangouri, V., & Talei, A. (2021). Prognostic Role of Lymphovascular Invasion in Patients with Early Breast Cancer. Indian Journal of Surgical Oncology, 12(4), 671–677. https://doi.org/10.1007/s13193-021-01367-9

Buzdar, A. U., Ibrahim, N. K., Francis, D., Booser, D. J., Thomas, E. S., Theriault, R. L., Pusztai, L., Green, M. C., Arun, B. K., Giordano, S. H., Cristofanilli, M., Frye, D. K., Smith, T. L., Hunt, K. K., Singletary, S. E., Sahin, A. A., Ewer, M. S., Buchholz, T. A., Berry, D., & Hortobagyi, G. N. (2005). Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer. Journal of Clinical Oncology, 23(16), 3676–3685. https://doi.org/10.1200/JCO.2005.07.032

Chica-Parrado, M. R., Godoy-Ortiz, A., Jiménez, B., Ribelles, N., Barragan, I., & Alba, E. (2020). Resistance to Neoadjuvant Treatment in Breast Cancer: Clinicopathological and Molecular Predictors. Cancers, 12(8), 2012. https://doi.org/10.3390/cancers12082012

Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., Swain, S. M., Prowell, T., Loibl, S., Wickerham, D. L., Bogaerts, J., Baselga, J., Perou, C., Blumenthal, G., Blohmer, J., … von Minckwitz, G. (2014). Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. The Lancet, 384(9938), 164–172. https://doi.org/10.1016/S0140-6736(13)62422-8

Ding, Y., Ding, K., He, X., Mo, W., Liang, C., Gong, L., Huang, Y., & Ding, X. (2023). The Value of Neoadjuvant Anthracycline-Based Regimens for HER2-Positive Breast Cancer: A Systematic Review and Meta-analysis Including 1366 Patients. Clinical Medicine Insights: Oncology, 17. https://doi.org/10.1177/11795549231195293

Fazal, F., Bashir, M. N., Adil, M. L., Tanveer, U., Ahmed, M., Chaudhry, T. Z., Ijaz, A. A., & Haider, M. (2023). Pathologic Complete Response Achieved in Early-Stage HER2-Positive Breast Cancer After Neoadjuvant Therapy With Trastuzumab and Chemotherapy vs. Trastuzumab, Chemotherapy, and Pertuzumab: A Systematic Review and Meta-Analysis of Clinical Trials. Cureus. https://doi.org/10.7759/cureus.39780

Gaibar, M., Beltrán, L., Romero-Lorca, A., Fernández-Santander, A., & Novillo, A. (2020). Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2 -Positive Breast Cancer. Journal of Oncology, 2020, 1–13. https://doi.org/10.1155/2020/6375956

Gianni, L., Pienkowski, T., Im, Y.-H., Roman, L., Tseng, L.-M., Liu, M.-C., Lluch, A., Staroslawska, E., de la Haba-Rodriguez, J., Im, S.-A., Pedrini, J. L., Poirier, B., Morandi, P., Semiglazov, V., Srimuninnimit, V., Bianchi, G., Szado, T., Ratnayake, J., Ross, G., & Valagussa, P. (2012). Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. The Lancet Oncology, 13(1), 25–32. https://doi.org/10.1016/S1470-2045(11)70336-9

Hall, B. J., Bhojwani, A. A., Wong, H., Law, A., Flint, H., Ahmed, E., Innes, H., Cliff, J., Malik, Z., O’Hagan, J. E., Hall, A., Sripadam, R., Tolan, S., Ali, Z., Hart, C., Errington, D., Alam, F., Giuliani, R., Mehta, S., … Palmieri, C. (2022). Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience. The Breast Journal, 2022, 1–10. https://doi.org/10.1155/2022/7146172

Hashim, H. T., Ramadhan, M. A., Theban, K. M., Bchara, J., El-Abed-El-Rassoul, A., & Shah, J. (2021). Assessment of breast cancer risk among Iraqi women in 2019. BMC Women’s Health, 21(1), 412. https://doi.org/10.1186/s12905-021-01557-1

Holmes, D., Colfry, A., Czerniecki, B., Dickson-Witmer, D., Francisco Espinel, C., Feldman, E., Gallagher, K., Greenup, R., Herrmann, V., Kuerer, H., Malik, M., Manahan, E., O’Neill, J., Patel, M., Sebastian, M., Wheeler, A., & Kass, R. (2015). Performance and Practice Guideline for the Use of Neoadjuvant Systemic Therapy in the Management of Breast Cancer. Annals of Surgical Oncology, 22(10), 3184–3190. https://doi.org/10.1245/s10434-015-4753-3

Hurvitz, S. A., Hu, Y., O’Brien, N., & Finn, R. S. (2013). Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treatment Reviews, 39(3), 219–229. https://doi.org/10.1016/j.ctrv.2012.04.008

Ishii, K., Morii, N., & Yamashiro, H. (2019). Pertuzumab in the treatment of HER2-positive breast cancer: an evidence-based review of its safety, efficacy, and place in therapy. Core Evidence, Volume 14, 51–70. https://doi.org/10.2147/CE.S217848

Kim, J.-Y., Nam, S. J., Lee, J. E., Yu, J., Chae, B. J., Lee, S. K., Ryu, J. M., Ahn, J. S., Im, Y.-H., Kim, S. W., & Park, Y. H. (2022). Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience. Cancer Research and Treatment, 54(4), 1091–1098. https://doi.org/10.4143/crt.2021.901

Korde, L. A., Somerfield, M. R., Carey, L. A., Crews, J. R., Denduluri, N., Hwang, E. S., Khan, S. A., Loibl, S., Morris, E. A., Perez, A., Regan, M. M., Spears, P. A., Sudheendra, P. K., Symmans, W. F., Yung, R. L., Harvey, B. E., & Hershman, D. L. (2021). Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. Journal of Clinical Oncology, 39(13), 1485–1505. https://doi.org/10.1200/JCO.20.03399

Liu, Y. L., Saraf, A., Lee, S. M., Zhong, X., Hibshoosh, H., Kalinsky, K., & Connolly, E. P. (2016). Lymphovascular invasion is an independent predictor of survival in breast cancer after neoadjuvant chemotherapy. Breast Cancer Research and Treatment, 157(3), 555–564. https://doi.org/10.1007/s10549-016-3837-5

Liu, Y., Wu, M., Tan, W., Gong, J., & Ma, J. (2022). Efficacy Evaluation of Neoadjuvant Chemotherapy in Breast Cancer by MRI. Contrast Media & Molecular Imaging, 2022(1). https://doi.org/10.1155/2022/4542288

Łukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanisławek, A. (2021). Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review. Cancers, 13(17), 4287. https://doi.org/10.3390/cancers13174287

Pathak, M., Dwivedi, S. N., Deo, S. V. S., Thakur, B., Sreenivas, V., & Rath, G. K. (2018). Neoadjuvant chemotherapy regimens in treatment of breast cancer: a systematic review and network meta-analysis protocol. Systematic Reviews, 7(1), 89. https://doi.org/10.1186/s13643-018-0754-1

Pondé, N. F., Zardavas, D., & Piccart, M. (2019). Progress in adjuvant systemic therapy for breast cancer. Nature Reviews Clinical Oncology, 16(1), 27–44. https://doi.org/10.1038/s41571-018-0089-9

Schettini, F., Pascual, T., Conte, B., Chic, N., Brasó-Maristany, F., Galván, P., Martínez, O., Adamo, B., Vidal, M., Muñoz, M., Fernández-Martinez, A., Rognoni, C., Griguolo, G., Guarneri, V., Conte, P. F., Locci, M., Brase, J. C., Gonzalez-Farre, B., Villagrasa, P., … Prat, A. (2020). HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. Cancer Treatment Reviews, 84, 101965. https://doi.org/10.1016/j.ctrv.2020.101965

Schneeweiss, A., Chia, S., Hickish, T., Harvey, V., Eniu, A., Hegg, R., Tausch, C., Seo, J. H., Tsai, Y.-F., Ratnayake, J., McNally, V., Ross, G., & Cortés, J. (2013). Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Annals of Oncology, 24(9), 2278–2284. https://doi.org/10.1093/annonc/mdt182

Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., Mackey, J., Glaspy, J., Chan, A., Pawlicki, M., Pinter, T., Valero, V., Liu, M.-C., Sauter, G., von Minckwitz, G., Visco, F., Bee, V., Buyse, M., Bendahmane, B., … Crown, J. (2011). Adjuvant Trastuzumab in HER2-Positive Breast Cancer. New England Journal of Medicine, 365(14), 1273–1283. https://doi.org/10.1056/NEJMoa0910383

Spring, L. M., Fell, G., Arfe, A., Sharma, C., Greenup, R., Reynolds, K. L., Smith, B. L., Alexander, B., Moy, B., Isakoff, S. J., Parmigiani, G., Trippa, L., & Bardia, A. (2020). Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. Clinical Cancer Research, 26(12), 2838–2848. https://doi.org/10.1158/1078-0432.CCR-19-3492

Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., Clark, E., Ross, G., Benyunes, M. C., & Cortés, J. (2015). Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer. New England Journal of Medicine, 372(8), 724–734. https://doi.org/10.1056/NEJMoa1413513

Tse, T., Sehdev, S., Seely, J., Gravel, D. H., Clemons, M., Cordeiro, E., & Arnaout, A. (2021). Neoadjuvant Chemotherapy in Breast Cancer: Review of the Evidence and Conditions That Facilitated Its Use during the Global Pandemic. Current Oncology, 28(2), 1338–1347. https://doi.org/10.3390/curroncol28020127

von Minckwitz, G., Procter, M., de Azambuja, E., Zardavas, D., Benyunes, M., Viale, G., Suter, T., Arahmani, A., Rouchet, N., Clark, E., Knott, A., Lang, I., Levy, C., Yardley, D. A., Bines, J., Gelber, R. D., Piccart, M., & Baselga, J. (2017). Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. New England Journal of Medicine, 377(2), 122–131. https://doi.org/10.1056/NEJMoa1703643

Wuerstlein, R., & Harbeck, N. (2017). Neoadjuvant Therapy for HER2-positive Breast Cancer. Reviews on Recent Clinical Trials, 12(2), 81–92. https://doi.org/10.2174/1574887112666170202165049

Yu, L., Fu, F., Li, J., Huang, M., Zeng, B., Lin, Y., Mei, Q., Lv, J., & Wang, C. (2020). Dual HER2 Blockade versus a Single Agent in Trastuzumab-Containing Regimens for HER2-Positive Early Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Oncology, 2020, 1–13. https://doi.org/10.1155/2020/5169278